scholarly journals Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (26) ◽  
pp. 40756-40766 ◽  
Author(s):  
Jun Won Kim ◽  
Jinsil Seong ◽  
Ik Jae Lee ◽  
Joong Yeol Woo ◽  
Kwang-Hyub Han
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase I ◽  
Dose Escalation ◽  
Stereotactic Body Radiotherapy ◽  
Intensity Modulated Radiotherapy ◽  
Dose Escalation Study ◽  
Intensity Modulated

Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1)

2012 ◽  
Vol 18 (5) ◽  
pp. 784-791 ◽  
Author(s):  
Mariangela Massaccesi ◽  
Marica Ferro ◽  
Savino Cilla ◽  
Mario Balducci ◽  
Francesco Deodato ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Escalation ◽  
Intensity Modulated Radiotherapy ◽  
Dose Escalation Study ◽  
Intensity Modulated

Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study

2019 ◽  
Vol 49 (9) ◽  
pp. 856-861 ◽  
Author(s):  
Kei Ito ◽  
Satoshi Kito ◽  
Yujiro Nakajima ◽  
Takuya Shimizuguchi ◽  
Hiroaki Ogawa ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cervical Cancer ◽  
Phase I ◽  
Dose Escalation ◽  
Stereotactic Body Radiotherapy ◽  
Phase I Clinical Trial ◽  
Recommended Dose ◽  
Intracavitary Brachytherapy ◽  
Dose Escalation Study

A phase I clinical trial was conducted to determine the recommended dose of SBRT boost for cervical cancer. The recommended dose was 22.5 Gy in three fractions.

Sign in / Sign up

Export Citation Format

Share Document